Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) FCF Margin (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed FCF Margin for 12 consecutive years, with 258.61% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin fell 19655.0% year-over-year to 258.61%, compared with a TTM value of 63.67% through Sep 2025, up 584.0%, and an annual FY2024 reading of 62.66%, down 723.0% over the prior year.
  • FCF Margin was 258.61% for Q3 2025 at CytomX Therapeutics, down from 84.57% in the prior quarter.
  • Across five years, FCF Margin topped out at 39.58% in Q1 2023 and bottomed at 465.14% in Q1 2022.
  • Average FCF Margin over 5 years is 158.55%, with a median of 84.57% recorded in 2025.
  • The sharpest move saw FCF Margin crashed -169908bps in 2021, then surged 50472bps in 2023.
  • Year by year, FCF Margin stood at 268.69% in 2021, then skyrocketed by 106bps to 16.81% in 2022, then tumbled by -580bps to 80.67% in 2023, then surged by 35bps to 52.47% in 2024, then tumbled by -393bps to 258.61% in 2025.
  • Business Quant data shows FCF Margin for CTMX at 258.61% in Q3 2025, 84.57% in Q2 2025, and 41.56% in Q1 2025.